Shattuck Labs, Inc. (STTK)
$6.09+2.01%Close
SELLCRISIS · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $292M
- Beta
- 1.10
- P/E (TTM)
- -11.49
- Short % float
- 24.20%
- Days to cover
- 6.0
- SI change
- +60.8%
- 1W
- -6.31%
- 1M
- -1.77%
- vs SPY 1W
- -6.73%
- vs SPY 1M
- -3.83%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 6
- GROWTH
- 4
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-26.1%
REV YoY-
ROE-43.6%
EPS YoY-
ROA-23.8%
GROSS-751
OP-5579
NET-5257
[VALUATION]
P/E TTM-11.49
P/E FWD-
SECTOR PE20.54
INDUSTRY PE14.03
P/B3.60
P/FCF-
EV/EBITDA-9.68
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.27
ALTMAN Z-
CURR RATIO27.59
ND/EBITDA-
BETA1.10
Company news
FAQ
- What is LOPJLB’s current signal on STTK?
- LOPJLB’s latest quantitative signal on Shattuck Labs, Inc. (STTK) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is STTK in?
- Shattuck Labs, Inc. (STTK) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Shattuck Labs, Inc. (STTK) do?
- Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and per…